Forum Discussion
Disappointing news.
I just read on face book that CDK inhibitor Ribociclib has been rejected for listing on the PBS. This is very very disappointing news when we have metastatic breast cancer and are always hoping that ...
I am struggling with how the two Ibrance and Ribociclib - CDk4/6 inh - av in USA since 2015, and early 2017, available in Canada and Eastern Europe are still not on PBS in Australia. Wow!
Well there is now Abemaciclib to also consider, it's numbers even in pretreated individuals are strong, much less neutropenia, albeit diarrhoea - looking good with Keytruda in early work, can cross Blood Brain Barrier - well this have to get TGA before anything else.
waiting for the March PBS review
Bugger, come on PBS - what do we move to Canada to get treatment??
Well there is now Abemaciclib to also consider, it's numbers even in pretreated individuals are strong, much less neutropenia, albeit diarrhoea - looking good with Keytruda in early work, can cross Blood Brain Barrier - well this have to get TGA before anything else.
waiting for the March PBS review
Bugger, come on PBS - what do we move to Canada to get treatment??